Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With Ascending Doses of JVRS-100 Adjuvant

NCT00662272 is registered in ClinicalTrials.gov with Colby Pharmaceutical Company as lead sponsor.

NCT NCT00662272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00662272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With Ascending Doses of JVRS-100 Adjuvant
Lead sponsor
Colby Pharmaceutical Company
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
December 31, 2009
Enrollment
128 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza